TORNTPHARM vs VENUSREM: Stock Comparison
TORRENT PHARMACEUTICALS L is the larger company by market capitalisation. TORRENT PHARMACEUTICALS L shows a higher ROE, a higher dividend yield and faster revenue growth, while VENUSREM shows a lower P/E, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
TORNTPHARM leads 5; VENUSREM leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| Live Price | ₹4,617.1 | ₹1,796.7 |
| Day Change | -2.1% | 0.03% |
| Volume | 2.54 L | 1.17 L |
| 52-Week High | ₹5,250 | ₹1,880 |
| 52-Week Low | ₹3,480.6 | ₹432.1 |
| Distance from 52W High | -12.06% | -4.43% |
Valuation
| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| Market Cap | ₹1.78 L Cr | ₹2,233 Cr |
| P/E Ratio | 72.55x | 19.22x |
| P/B Ratio | 18.86x | 3.36x |
| EPS | ₹14.54 | ₹19.1 |
| Book Value | ₹519.58 | ₹496.56 |
| Dividend Yield | 0.8% | 0.56% |
Growth
| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 41.8% | 33% |
| EPS Growth (TTM YoY) | -21.7% | 126.4% |
| Qtr Sales Growth | -15.5% | -0.03% |
| Qtr Profit Growth | -13.07% | 11.14% |
Profitability & Leverage
| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| ROE | 25.93% | 15.49% |
| ROCE | 11.33% | 16.2% |
| Net Margin | 15.73% | 13.35% |
| Operating Margin | 30.23% | 17.56% |
| Debt to Equity | 1.68x | 0x |
Shareholding
As of Jul 2026 • change vs previous quarter| Metric | TORNTPHARM | VENUSREM |
|---|---|---|
| Promoter Holding | 60.78%▼ 7.53 pp | 41.76% |
| FII Holding | 17.97%▲ 2.53 pp | 2.92%▲ 0.12 pp |
| DII Holding | 12.87%▲ 3.04 pp | 0.89%▼ 0.31 pp |
| Public Holding | 8.38%▲ 1.96 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: TORRENT PHARMACEUTICALS L and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.